Robert Alexander, PhD

Chief Executive Officer

Dr. Alexander has been involved in the formation and leadership of numerous biotechnology companies. Dr. Alexander was CEO of ZS Pharma where he led the initial public offering and sale of ZS Pharma to AstraZeneca. Prior to ZS Pharma, Dr. Alexander was a Director at Alta Partners, a venture capital firm, and was also Executive Chairman and interim CEO of SARcode Bioscience. During his time at Alta Partners, he led investments in SARcode Bioscience (acquired by Shire), Lumena Pharmaceuticals (acquired by Shire), ZS Pharma (acquired by AstraZeneca), and Allakos. Prior to Alta Partners, Dr. Alexander was a Principal in MPM Capital’s BioEquities Fund. Robert joined MPM from Genentech, where he worked in the Business Development group.

Dr. Alexander holds a PhD from the University of North Carolina at Chapel Hill and a Bachelor of Science in Zoology from Miami University of Ohio.

Mary Cromwell, PhD

Chief Technical Officer

Dr. Cromwell has more than 30 years’ experience in the biotechnology industry. Prior to joining Allakos, Dr. Cromwell was Vice President for Quality, Drug Substance at Genentech/Roche. She began her career at Genentech in the Pharmaceutical Development group where she developed formulations for several molecules in various stages of development. She has held leadership positions in Protein Analytical Chemistry, Pharmaceutical Development, and Global Biologics Manufacturing Sciences and Technologies & Global Packaging Development prior to her role in Quality. Dr. Cromwell was directly involved in the licensure of numerous Genentech/Roche products, including Avastin® and Perjeta®. She served as a member of the Genentech Foundation Board, a non-profit organization that provided funding to improve the success of students from underrepresented groups in post-secondary STEM education.

Dr. Cromwell received a BS in Chemistry from West Virginia University, an MS in Biophysical Chemistry from the University of California-Berkeley, and a PhD in Pharmaceutical Sciences from the University of Colorado-Denver.

Chin Lee, MD MPH

Chief Medical Officer

Dr. Lee has over 20 years of clinical research & development experience in the biopharmaceutical industry and academia across multiple therapeutic areas, including rheumatology, dermatology, allergy & asthma, and gastroenterology, focused on the development of small molecules and biologic therapies for immune mediated conditions. Prior to Allakos, Dr. Lee served as the Chief Medical Officer at Connect Biopharma, a clinical-stage company focused on development of innovative therapies for chronic inflammatory diseases based on T cell-driven research. Dr. Lee also previously served as Vice President, Head of Clinical Science, and Chief Medical Officer at Theravance Biopharma, Inc, Lead Group Medical Director within the Genentech Research & Early Development (gRED) group, as well held roles of increasing responsibility within the Immunology Therapeutic Area at Eli Lilly & Co., and the Immunoscience Group at Abbott (now Abbvie). During his time in industry, Dr. Lee has successfully led the submission of global regulatory filings and participated in product commercialization across multiple autoimmune and immunology disease indications.

Prior to entering the biopharmaceutical industry, Dr. Lee was on the academic faculty at the Northwestern University Feinberg School of Medicine in the Division of Rheumatology. Dr. Lee received his BS in Biology and an MD from the University of North Carolina at Chapel Hill, and an MPH from Northwestern University.

Baird Radford


Mr. Radford has over 25 years of public company finance and leadership experience at companies in multiple industries and various stages of growth including providing financial operations leadership to commercial-stage companies. Prior to Allakos, as Senior Vice President of Finance at Aimmune Therapeutics, Mr. Radford was responsible for all aspects of strategic and operational finance activities supporting the launch of its first approved product, including financial planning, controllership, tax and treasury functions. Prior to working at Aimmune Therapeutics, he served as the Chief Financial Officer at HeartFlow, a medical technology company with commercial operations in the United States, Canada, Europe and Japan. Prior to joining HeartFlow, Mr. Radford served as Vice President of Finance at Intuitive Surgical, with responsibility for financial planning and analysis, investor relations and enterprise analytics. Prior to Intuitive Surgical, Mr. Radford held various positions at eBay, including Vice President of Finance for Marketplaces Europe, as well as Vice President, Corporate Controller, and Chief Accounting Officer. Mr. Radford began his career in the audit practice of PricewaterhouseCoopers.

Mr. Radford has a BBA from Ohio University.

Adam Tomasi, PhD


Prior to joining Allakos, Dr. Tomasi was Chief Scientific Officer and Head of Corporate Development at ZS Pharma where he led scientific, business development, and investor relation functions through the company’s initial public offering and sale to AstraZeneca. Before joining ZS Pharma, Dr. Tomasi was a Principal at Alta Partners where he contributed to investments in ZS Pharma (acquired by AstraZeneca), Lumena Pharmaceuticals (acquired by Shire), Excaliard (acquired by Pfizer), ChemGenex (acquired by Cephalon), Achaogen, Immune Design and Allakos. Dr. Tomasi served as a drug discovery scientist with Gilead Sciences and Cytokinetics.

Dr. Tomasi holds a Bachelor of Science in Chemistry from the University of California, Berkeley, an MBA from MIT and a PhD in Chemistry from the University of California, Irvine.